Immunodeficiency Virus (e.g., Hiv, Etc.) Patents (Class 424/188.1)
  • Patent number: 11345726
    Abstract: The present invention provides a particle comprising a polypeptide and at least one antigen, and a composition comprising thereof.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: May 31, 2022
    Assignee: VLP Theranentics. Inc.
    Inventors: Ryuji Ueno, Wataru Akahata
  • Patent number: 11260081
    Abstract: Provided are nucleic acid constructs, Toxoplasma comprising same, pharmaceutical compositions comprising same and methods using same for delivering a protein-of-interest to a tissue-of-interest of a subject, such as the CNS and further treating a pathology which is treatable by administration of a therapeutic polypeptide in a central nervous system of the subject.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: March 1, 2022
    Assignees: Ramot at Tel-Aviv University Ltd., The Universitv Court of the University of Glasgow
    Inventors: Oded Rechavi, Shahar Bracha, Lilach Sheiner
  • Patent number: 11235069
    Abstract: The invention provides compositions comprising a carrier comprising a continuous phase of a hydrophobic substance, liposomes, and a polynucleotide, and methods for using such compositions for delivering a polynucleotide to a subject.
    Type: Grant
    Filed: January 23, 2019
    Date of Patent: February 1, 2022
    Assignee: IMMUNOVACCINE TECHNOLOGIES INC.
    Inventors: Marc Mansour, Mohan Karkada, Genevieve Mary Weir
  • Patent number: 11149069
    Abstract: The invention provides compositions and methods related to conformationally stabilizing primate immunodeficiency virus envelope glycoprotein trimers.
    Type: Grant
    Filed: July 31, 2013
    Date of Patent: October 19, 2021
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Joseph Sodroski, Youdong Mao
  • Patent number: 11129889
    Abstract: Provided herein are recombinant nucleic acid sequences derived from the C-terminal domain of the HIV-1 gp41 protein, and more specifically compositions and methods for using these epitopes to develop vaccine protection against HIV. Also provided here are monoclonal antibodies that specifically bind to these recombinant nucleic acid sequences derived from the C-terminal domain of the HIV-1 gp41 protein.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: September 28, 2021
    Inventors: Ruth M. Ruprecht, Hemant K. Vyas
  • Patent number: 11066464
    Abstract: Antibodies that bind to the circumsporozoite protein (CSP) of Plasmodium falciparum. Use of such antibodies as anti-malarial agents, to confer protection against infection by malarial parasites such as P. falciparum by insect vector transmission. Diagnosis of malaria using anti-CSP antibodies. Methods of determining efficacy of candidate vaccine compositions in development and testing of anti-malarial vaccines.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: July 20, 2021
    Assignees: KYMAB LIMITED, ATRECA, INC.
    Inventors: Qi Liang, Sean Matthew Carroll, Daniel Eric Emerling, Allan Bradley, Paul Kellam, {hacek over (S)}pela Binter, Simon James Watson
  • Patent number: 11017882
    Abstract: The invention provides a method for predicting whether a binding peptide, which binds to a target peptide presented by a Major Histocompatibility Complex (MHC) and is for administration to a subject, has the potential to cross react with another peptide in the subject in vivo. The method comprises the steps of identifying at least one binding motif in the target peptide to which the binding peptide binds; and searching for peptides that are present in the subject that comprise the at least one binding motif and that are not the target peptide. The presence of one or more such peptides indicates that the binding peptide has the potential to cross react in vivo.
    Type: Grant
    Filed: June 17, 2015
    Date of Patent: May 25, 2021
    Assignees: Immunocore Limited, Adaptimmune Limited
    Inventors: Brian John Cameron, Annelise Brigitte Vuidepot, Bent Karsten Jakobsen
  • Patent number: 11007255
    Abstract: The invention provides a vaccine comprising a nucleic acid molecule that encodes a dog telomerase reverse transcriptase (dTERT) antigen, as well as methods of using the vaccine to induce an immune response against a TERT and to treat cancer in a mammal.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: May 18, 2021
    Assignee: Inovio Pharmaceuticals, Inc.
    Inventor: Jian Yan
  • Patent number: 10987420
    Abstract: Highly effective vaccine compositions are constructed according to the methods of this invention. The methods are amenable to use with any peptidic antigen sequence and involve covalent attachment of an immunostimulatory nucleotide sequence to an antigenic peptide sequence. Preferred antigenic peptides are fusion peptides made up of one or more CTL epitope peptides in sequence fused to a T helper peptide.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: April 27, 2021
    Assignee: CITY OF HOPE
    Inventor: Don J. Diamond
  • Patent number: 10937524
    Abstract: The invention provides a method for predicting whether a binding peptide, which binds to a target peptide presented by a Major Histocompatibility Complex (MHC) and is for administration to a subject, has the potential to cross react with another peptide in the subject in vivo. The method comprises the steps of identifying at least one binding motif in the target peptide to which the binding peptide binds; and searching for peptides that are present in the subject that comprise the at least one binding motif and that are not the target peptide. The presence of one or more such peptides indicates that the binding peptide has the potential to cross react in vivo.
    Type: Grant
    Filed: June 17, 2015
    Date of Patent: March 2, 2021
    Assignees: Immunocore Limited, Adaptimmune Limited
    Inventors: Brian John Cameron, Annelise Brigitte Vuidepot, Bent Karsten Jakobsen
  • Patent number: 10927157
    Abstract: The disclosure provides helix grafted proteins, methods of producing helix grafted proteins and methods of use of helix grafted proteins as inhibitors of protein-protein interactions involved in disease pathogenesis.
    Type: Grant
    Filed: August 7, 2019
    Date of Patent: February 23, 2021
    Assignee: COLORADO STATE UNIVERSITY RESEARCH FOUNDATION
    Inventors: Brian R. McNaughton, Susanne N. Walker, Rachel L. Tennyson, Alan J. Kennan
  • Patent number: 10758609
    Abstract: The subject invention concerns methods and materials for inducing an immune response in an animal or person against an immunodeficiency virus, such as HIV, SIV, or FIV. In one embodiment, a method of the invention comprises administering one or more antigens and/or immunogens to the person or animal wherein the antigen and/or immunogen comprises one or more evolutionarily conserved epitopes of immunodeficiency viruses. In one embodiment, the epitope is one that is conserved between HIV and FIV.
    Type: Grant
    Filed: September 25, 2016
    Date of Patent: September 1, 2020
    Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
    Inventor: Janet K. Yamamoto
  • Patent number: 10729759
    Abstract: The invention provides an aqueous acidic formulation suitable for use as in the preparation of a pharmaceutically acceptable fluorocarbon-linked peptide formulation, which aqueous formulation comprises a first fluorocarbon-linked peptide, wherein: the peptide linked to the fluorocarbon is at least 20 amino acid residues long, comprises at least 50% hydrophobic amino acid residues and has an isoelectric point greater than or equal to 7; and the fluorocarbon-linked peptide is present in micelles.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: August 4, 2020
    Assignee: Altimmune UK Limited
    Inventors: Carlton Bradley Brown, Bertrand Victor Gilbert Georges, Jean Francois Thaburet
  • Patent number: 10563193
    Abstract: The invention relates to a glycopolypeptide that includes one or more modified amino acid residues having a sidechain comprising a monosaccharide or an oligosaccharide, wherein the glycopolypeptide binds specifically to a carbohydrate-binding monoclonal antibody with an affinity of less than 100 nM. Immunogenic conjugates that include the glycopolypeptide, and pharmaceutical compositions that include the glycopolypeptide or the immunogenic conjugate are also disclosed. Various method of using the glycopolypeptides, immunogenic conjugates, and pharmaceutical compositions are disclosed, including inducing an immune response, inhibiting viral or bacterial infection, treating a cancerous condition, and detecting a neutralizing antibody.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: February 18, 2020
    Assignee: Brandeis University
    Inventors: Isaac J. Krauss, Satoru Horiya
  • Patent number: 10556926
    Abstract: The present invention relates to antimicrobial peptides of the general formula AxByCz with x, z?1, y?3 and x+y+z?50, where A and C, in each case independently of one another, have at least 65% basic amino acids and B has at least 65% hydrophobic and/or nonpolar amino acids and comprises a direct sequence of at least three hydrophobic amino acids. Moreover, a medical use of the peptides, a conjugate and an antimicrobial composition are indicated.
    Type: Grant
    Filed: February 9, 2015
    Date of Patent: February 11, 2020
    Assignee: Fraunhofer-Gesellschaft
    Inventors: Karsten Rapsch, Markus v. Nickisch-Rosenegk
  • Patent number: 10517942
    Abstract: Creation of HIV-1 vaccine immunogens based on glycopeptide scaffolds containing sequences from the V1/V2/V3 and C3 domains of HIV-1 gp120 that is able to bind multiple broadly neutralizing antibodies when expressed in mammalian cells that incorporate mannose-5 and mannose-9 glycans.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: December 31, 2019
    Assignee: The Regents of the University of California
    Inventors: Phillip Berman, Rachel Doran, Gabriel Byrne, Rebecca Dubois, Javier Morales, Bin Yu, Gerardo Perez, Kathryn Mesa, David Alexander
  • Patent number: 10508992
    Abstract: The invention is based on the use of photoluminescent probes for intracellular sensing of oxygen, especially assaying intracellular oxygen concentration. The photoluminescent probe comprises a suspension of polymeric particles having an average diameter in the 20 nm to 100 nm range, formed from an amphiphilic cationic co-polymer which is oriented in the formed particle to provide a hydrophobic core and a hydrophilic shell. The probe includes a hydrophobic oxygen-sensitive photoluminescent dye such as Pt-tetrakis(pentafluorophenyl)porphine, PtPFPP embedded in the hydrophobic core of the particle, and the co-polymer includes quaternary ammonium groups which provide hydrophilic and cationic character to the particle shell. The photoluminescent probe, which in use is provided in the form of an aqueous suspension of probe, is incubated with live mammalian cells in a suitable growth medium for a period of time to allow the probe particles passively load into the cells.
    Type: Grant
    Filed: October 22, 2010
    Date of Patent: December 17, 2019
    Assignee: University College Cork, National University of Ir Cork
    Inventors: Dmitri Papkovsky, Andreas Fercher, Ingo Klimant, Sergey Borisov, Alexander Zhdanov
  • Patent number: 10487125
    Abstract: The present invention relates to a nucleic acid construct comprising: a nucleic acid sequence encoding an ice structuring protein (ISP) comprising the sequence set out in SEQ ID NO: 1 or a sequence at least 80% identical thereto or comprising the sequence set out in amino acids 21 to 261 of SEQ ID NO: 1 or a sequence at least 80% identical thereto; and, linked operably thereto, control sequences permitting expression of the nucleic acid sequence in a filamentous fungal host cell. The construct may be used in a method for the production of an ISP, wherein the ISP is expressed in a filamentous fungal host cell.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: November 26, 2019
    Assignee: DSM IP ASSETS B.V.
    Inventors: René Marcel De Jong, Petrus Jacobus Theodorus Dekker
  • Patent number: 10478444
    Abstract: A method of treating or preventing a systemic viral infection in a mammal by administering a pharmaceutically acceptable composition selected from the group consisting of squalamine, an active isomer thereof, and an active analogue thereof, via a dosing regimen that delivers effective antiviral concentrations of squalamine. Also compositions for achieving the systemic antiviral effect.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: November 19, 2019
    Assignee: Enterin, Inc.
    Inventor: Michael Zasloff
  • Patent number: 10434136
    Abstract: The present invention relates to peptides, nucleic acids, and cells for use in the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention specifically relates to three novel peptide sequences and variants thereof derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: October 8, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Hans-Georg Rammensee, Stefan Stevanovic, Cecile Gouttefangeas, Toni Weinschenk, Peter Lewandrowski
  • Patent number: 10428128
    Abstract: The disclosure provides helix grafted proteins, methods of producing helix grafted proteins and methods of use of helix grafted proteins as inhibitors of protein-protein interactions involved in disease pathogenesis.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: October 1, 2019
    Assignee: Colorodo State University Research Foundation
    Inventors: Brian R. McNaughton, Susanne N. Walker, Rachel L. Tennyson, Alan J. Kennan
  • Patent number: 10426831
    Abstract: The invention provides compositions, methods, and kits for the treatment or prevention of viral infections. The polyvalent (e.g., 2-valent) vaccines described herein incorporate computationally-optimized viral polypeptides that can increase the diversity or breadth and depth of cellular immune response in vaccinated subjects.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: October 1, 2019
    Assignees: Beth Israel Deaconess Medical Center, Inc., TRIAD NATIONAL SECURITY, LLC
    Inventors: Dan H. Barouch, Bette T. Korber, William M. Fischer
  • Patent number: 10273268
    Abstract: Immunogenic compositions containing a human immunodeficiency virus (HIV) gp140 protein, sorbitol, polysorbate 20, and histidine buffer are described. The described immunogenic compositions are advantageous in that they are stable at refrigerated temperature for extended periods of time, and are compatible with an adjuvant. Also described are methods of using the immunogenic compositions to induce an immune response against an HIV in a subject. The immunogenic compositions can be administered alone, or in combination with one or more additional HIV antigens, or one or more adenovirus vectors encoding the one or more additional HIV antigens.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: April 30, 2019
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Thierry-Thien Nguyen, Mark Bruner
  • Patent number: 10232052
    Abstract: The invention provides compositions comprising a carrier comprising a continuous phase of a hydrophobic substance, liposomes, and a polynucleotide, and methods for using such compositions for delivering a polynucleotide to a subject.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: March 19, 2019
    Assignee: IMMUNOVACCINE TECHNOLOGIES INC.
    Inventors: Marc Mansour, Mohan Karkada, Genevieve Mary Weir
  • Patent number: 10195290
    Abstract: The present invention relates to methods of preparing a therapeutic exosome using a protein newly-identified to be enriched on the surface of exosomes. Specifically, the present invention provides methods of using the proteins for affinity purification of exosomes. It also provides methods of localizing a therapeutic peptide on exosomes, and targeting exosomes to a specific organ, tissue or cell by using the proteins. The methods involve generation of surface-engineered exosomes that include one or more of the exosome proteins at higher density, or a variant or a fragment of the exosome protein.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: February 5, 2019
    Assignee: Codiak BioSciences, Inc.
    Inventors: Kevin P. Dooley, Rane A. Harrison, Russell E. McConnell, Ke Xu, Damian J. Houde, Nikki Ross, Sonya Haupt, John D. Kulman, Douglas E. Williams
  • Patent number: 10058594
    Abstract: Depression and PTSD are treated by administration of hCG, or an hCG analog, or a prodrug or metabolite of hCG or an hCG analog, in an amount equivalent to a subcutaneous dose of 50-200 IU, preferably 120-170 IU, more preferably 140-160 IU, of hCG per day.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: August 28, 2018
    Assignee: Neuralight HD, LLC
    Inventors: Edson Conrad Hicks, Jr., Constance T. Dutton
  • Patent number: 9999664
    Abstract: The invention relates to an immunogenic HIV-1 gp120 mini V3 loop, which is a truncated version of the full-length gp120 V3 loop useful for crystallization with antibodies that recognize carbohydrate moieties. The invention also relates to the structure of a broadly neutralizing antibody as a complex with a glycosylated gp120 outer domain, as determined by crystallographic techniques, and the confirmation that a glycosylated gp120 outer domain has a functional relevant conformation, as well as the determination of key residues on a glycosylated gp120 outer domain, and uses thereof and compounds and compositions therefrom. Furthermore, the invention also relates to other peptides and mimetic peptides, which bind to broadly neutralizing antibodies.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: June 19, 2018
    Assignee: The Scripps Research Institute
    Inventors: Ian A. Wilson, Robyn L. Stanfield, Robert Pejchal
  • Patent number: 9988451
    Abstract: A method for inducing an immune response against HIV in a subject includes the step of preparing an HIV-1 gp120 envelope protein coding sequence particle having an N425K mutation, introducing the HIV-1 gp120 protein coding sequence particle having an N425K mutation into an expression construct using yeast homologous recombination, transfecting a cell with the expression construct, wherein the HIV-1 particle is secreted by the cell, and administering the secreted HIV-1 particle and a pharmaceutically acceptable carrier to the subject, wherein the secreted HIV-1 particle stimulates an immune response in the subject.
    Type: Grant
    Filed: October 27, 2014
    Date of Patent: June 5, 2018
    Assignee: Case Western Reserve University
    Inventors: Eric J. Arts, Annette Burkhouse
  • Patent number: 9983207
    Abstract: This disclosure relates generally to the field of immunological-based diagnostic assays including an assay to measure cell-mediated immunoresponsiveness. The present disclosure teaches diagnosis of a subject's exposure to an antigen based on cell-mediated immunoresponsiveness with enhanced sensitivity. Lymphocytes from a subject are contacted with at least a first set of peptides comprising at least one peptide of from 7 to 14 amino acid residues in length and a second set comprising at least one peptide of 16 amino acid residues or greater and the presence or elevation of an immune molecule is detected. The assay contemplated herein is capable of integration into standard pathology architecture to provide a diagnostic reporting system and to facilitate point of care clinical management.
    Type: Grant
    Filed: June 27, 2012
    Date of Patent: May 29, 2018
    Assignee: Cellestis Limited
    Inventor: Jeff Boyle
  • Patent number: 9975924
    Abstract: An approach of producing recombinant trimers that mimic native HIV-1 envelope trimers is developed. A recombinant protein forming the recombinant trimers encompasses a recombinant HIV-1 gp140 fused to a tag through a linker at C-terminus of the recombinant HIV-1 gp140. The linker is sufficiently long so that the tag is accessible for binding by a binding molecule bound on a solid matrix. After expressed in a cell, the recombinant protein is secreted into the culture medium and assembles into recombinant trimers therein. The recombinant trimers may be directly purified from the culture medium. Cleaved and uncleaved trimers from different clade viruses are produced.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: May 22, 2018
    Assignee: The Catholic University of America
    Inventors: Venigalla B. Rao, Wadad Alsalmi
  • Patent number: 9861693
    Abstract: This disclosure relates to recombinant bacteria, e.g. L. lactis, expressing heterologous pili containing human immunodeficiency virus (HIV) antigens. In certain embodiments, the recombinant bacteria are administered in combination with other HIV antigens, nucleic acids encoding HIV antigens, recombinant virus encoding HIV antigens, anti-viral agents and/or adjuvants in an effective amount to elicit a mucosal immune response against HIV.
    Type: Grant
    Filed: September 6, 2013
    Date of Patent: January 9, 2018
    Assignee: Emory University
    Inventors: Rama Rao Amara, June R. Scott, Bernard Quigley, Venkateswarlu Chamcha
  • Patent number: 9850473
    Abstract: The present invention provides for recombinant Endo-D and selected mutants that exhibit reduced hydrolysis activity and increased transglycosylation activity for the synthesis of glycoproteins wherein a desired sugar chain is added to a core fucosylated or nonfucosylated GlcNAc-protein acceptor by transglycosylation. Such recombinant Endo-D and selected mutants are useful for efficient glycosylation remodeling of IgG1-Fc domain.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: December 26, 2017
    Assignee: University of Maryland, Baltimore
    Inventor: Lai-Xi Wang
  • Patent number: 9782472
    Abstract: Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity.
    Type: Grant
    Filed: April 4, 2011
    Date of Patent: October 10, 2017
    Assignee: The Regents of The University of California
    Inventors: Phillip Berman, Sara O'Rourke, William Scott
  • Patent number: 9738688
    Abstract: The present application relates to novel HIV-1 envelope glycoproteins, which may be utilized as HIV-1 vaccine immunogens, and antigens for crystallization, electron microscopy and other biophysical, biochemical and immunological studies for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions, which are formulated into the vaccines of the present invention.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: August 22, 2017
    Assignees: INTERNATIONAL AIDS VACCINE INITIATIVE, THE SCRIPPS RESEARCH INSTITUTE, CORNELL UNIVERSITY
    Inventors: Michael Caulfield, Albert Cupo, Hansi Dean, Simon Hoffenberg, C. Richter King, P. J. Klasse, Andre Marozsan, John P. Moore, Rogier W. Sanders, Andrew Ward, Ian Wilson, Jean-Philippe Julien
  • Patent number: 9333246
    Abstract: Embodiments of the present invention illustrate methods of treating and preventing infection due to a pathogen such as a fungal pathogen. In particular, the present invention relates to compositions and methods for vaccinations against or treatment for a fungal organism in a non-immunocompromised or immunocompromised subject.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: May 10, 2016
    Assignee: GlobeImmune, Inc.
    Inventors: Claude P. Selitrennikoff, Tamara K Miller
  • Patent number: 9260479
    Abstract: Macrocyclization of amino acids or linear peptides upon reaction with amphoteric amino aldehydes and isocyanides is provided.
    Type: Grant
    Filed: March 16, 2010
    Date of Patent: February 16, 2016
    Assignee: The Governing Council of the University of Toronto
    Inventors: Andrei Yudin, Ryan Hili
  • Patent number: 9212208
    Abstract: The present invention relates to novel muteins derived from human tear lipocalin having affinity to human c-Met receptor tyrosin kinase (c-Met). The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.
    Type: Grant
    Filed: January 29, 2009
    Date of Patent: December 15, 2015
    Assignee: Pieris AG
    Inventors: Gabriele Matschiner, Andreas Hohlbaum, Martin Huelsmeyer, Stefan Trentmann
  • Patent number: 9161948
    Abstract: Oligonucleotide analogues conjugated to carrier peptides are provided. The disclosed compounds are useful for the treatment of various diseases, for example diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.
    Type: Grant
    Filed: November 17, 2011
    Date of Patent: October 20, 2015
    Assignee: Sarepta Therapeutics, Inc.
    Inventor: Gunnar J. Hanson
  • Patent number: 9060972
    Abstract: The present invention provides a recombinant hemagglutinin antigenic protein, a virus-like particle and a recombinant influenza virus. The present invention further provides a vaccine comprising the recombinant hemagglutinin antigenic protein, the virus-like particle or recombinant influenza virus.
    Type: Grant
    Filed: October 22, 2011
    Date of Patent: June 23, 2015
    Inventor: George Dacai Liu
  • Publication number: 20150147387
    Abstract: The present invention relates to a method of inducing the production in a patient of anti-HIV antibodies. The method comprises administering to a patient in need thereof an amount of at least one liposome-peptide conjugate in an amount sufficient to effect that induction. The peptide comprises a membrane external proximal region (MPER) epitope and the liposome comprises lysophosphorylcholine or phosphatidylserine.
    Type: Application
    Filed: February 3, 2015
    Publication date: May 28, 2015
    Inventors: Barton F. HAYNES, S. Munir Alam, Hua-Xin Liao
  • Publication number: 20150147348
    Abstract: The present invention relates to the field of vaccines directed against viruses of the HIV family. More particularly, it relates to an immunogenic compound comprising a peptide of the following formula (I) NH2-[Nt]y-P-W-N-X-S-X2-S-N-X3-X4-X-X6-X7-I-W-[Ct]z-COOH (I) which is covalently linked to a carrier protein consisting of a CRM197 protein. It also concerns a composition containing this immunogenic compound and the uses of these immunogenic compounds and compositions for preventing and/or treating a condition caused by the infection of an individual with a HIV virus.
    Type: Application
    Filed: May 30, 2013
    Publication date: May 28, 2015
    Inventors: Joël Crouzet, Raphaël Ho Tsong Fang, Dominique Desfontaines
  • Publication number: 20150132332
    Abstract: Provided are antigenic polypeptides of HIV envelope glycoproteins which are constructed based on amino acid mutation of attenuated live vaccine of Equine Infectious Anemia Virus, DNA constructions and recombinant virus vectors comprising polynucleotides encoding said polypeptides, antibodies against said polypeptides as well as uses thereof in preventing and treating HIV infection. Said antigenic polypeptides and vaccines can induce high titer neutralization antibodies against HIV in organism.
    Type: Application
    Filed: January 21, 2015
    Publication date: May 14, 2015
    Inventors: YIMING SHAO, LIANXING LIU, RONGXIAN SHEN
  • Publication number: 20150132255
    Abstract: The present invention relates to novel combinations of active agents and methods for the treatment of HIV infection and AIDS. In particular, the present invention relates to novel combinations of (1) therapeutic agents which can effect stabilisation of a complex between domains in certain HIV proteins with (2) HIV-specific vaccine peptides.
    Type: Application
    Filed: June 6, 2013
    Publication date: May 14, 2015
    Applicant: Bionor Immuno AS
    Inventors: Birger Sorensen, Mats Okvist, Arnt Ove Hovden, Maja Sommerfelt Gronvold, Lars Hoie, Anker Lundemose, Vidar Wendel Hansen
  • Publication number: 20150118319
    Abstract: This invention provides a peptide/nucleic acid composition for oral/mucosal, dual-modal activation of immune protection systems.
    Type: Application
    Filed: November 5, 2014
    Publication date: April 30, 2015
    Inventors: R. Holland Cheng, Li Xing
  • Patent number: 9017691
    Abstract: The invention provides compositions, methods, and kits for the treatment or prevention of viral infections. The polyvalent (e.g., 2-valent) vaccines described herein incorporate computationally-optimized viral polypeptides that can increase the diversity or breadth and depth of cellular immune response in vaccinated subjects.
    Type: Grant
    Filed: November 18, 2009
    Date of Patent: April 28, 2015
    Assignees: Beth Israel Deaconess Medical Center, Los Alamos National Security, LLC
    Inventors: Dan H. Barouch, Bette T. Korber, William M. Fischer
  • Patent number: 9011875
    Abstract: The present invention relates to mosaic HIV-1 group M Gag sequences and to a composition comprising same.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: April 21, 2015
    Assignees: Los Alamos National Security, LLC, Beth Israel Deaconess Medical Center, Duke University, The University of Alabama at Birmingham Research Foundation
    Inventors: Bette T. Korber, Simon Perkins, Tanmoy Bhattacharya, William M. Fischer, James Theiler, Norman Letvin, Barton F. Haynes, Beatrice H. Hahn, Karina Yusim, Carla Kuiken
  • Patent number: 9011873
    Abstract: The present invention relates to nucleic acids encoding mosaic clade M HIV-1 Env polypeptides and to compositions and vectors comprising same. The nucleic acids of the invention are suitable for use in inducing an immune response to HIV-1 in a human.
    Type: Grant
    Filed: April 26, 2011
    Date of Patent: April 21, 2015
    Assignees: Los Alamos National Security, LLC, Duke University, Beth Israel Deaconess Medical Center, The University of Alabama at Birmingham Research Foundation
    Inventors: Bette T. Korber, William Fischer, Hua-Xin Liao, Barton F. Haynes, Norman Letvin, Beatrice H. Hahn
  • Patent number: 9005631
    Abstract: Disclosed herein are isolated immunogens including variant hepatitis B surface antigens (HBsAgs). In an example, a variant HBsAg includes a HBsAg with one or more transmembrane domains of the HBsAg replaced with a gp41 antigenic insert. The antigenic insert can include an antigenic polypeptide fragment of gp41 including the membrane proximal region of gp41 and a transmembrane membrane region of gp41. The replacement of a membrane spanning domain of HBsAg with a membrane spanning domain of gp41 anchors gp41 into HBsAg in virtually the identical orientation as on HIV virions and correctly orients the nearby MPR on the lipid layer. Thus, the disclosed variant HBsAgs display the neutralization-sensitive MPR in association with a lipid layer, while presenting it at the most immunogenic site on HBsAg. Also disclosed are uses of these variant HBsAgs, and nucleic acids encoding variant HBsAgs, such as to induce an immune response to HIV-1.
    Type: Grant
    Filed: August 4, 2009
    Date of Patent: April 14, 2015
    Assignee: The United States of America as Represented by the Secretary of the Department of Health and Human Services
    Inventor: Ira Berkower
  • Publication number: 20150098960
    Abstract: Disclosed herein are compositions comprising a Human Immunodeficiency Virus (HIV) trans-activator of transcription (Tat) derivative polypeptide with increased immunostimulatory properties relative to the native Tat polypeptide, pharmaceutical compositions comprising the Tat derivative polypeptide, and methods of treating cancer using the Tat derivative polypeptide.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 9, 2015
    Inventors: Joshua Goldberg, Colin Bier
  • Patent number: 8999350
    Abstract: The invention relates to a method of preventing or treating acquired immunodeficiency syndrome (AIDS) in a patient, wherein the patient is administered with a Tat protein comprising amino acid sequence SEQ ID NO: 1 or 2, or a variant thereof capable of stimulating an immune response against Tat proteins.
    Type: Grant
    Filed: April 22, 2009
    Date of Patent: April 7, 2015
    Assignee: Universite d'Aix-Marseille
    Inventor: Erwann Loret